Unichem Laboratories (BSE:506690) - Stock Price, News & Analysis

506690 Stock Overview

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide.

506690 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	3/6
Dividends	0/6

Rewards

Became profitable this year

Risk Analysis

Large one-off items impacting financial results

Unichem Laboratories Limited Competitors

Hikal

BSE:524735

₹37.1b

Shilpa Medicare

BSE:530549

₹44.2b

Aarti Drugs

BSE:524348

₹45.1b

Gufic Biosciences

BSE:509079

₹30.3b

Price History & Performance

Summary of all time highs, changes and price drops for Unichem Laboratories
Historical stock prices
Current Share Price	₹549.60
52 Week High	₹579.80
52 Week Low	₹365.35
Beta	0.14
1 Month Change	5.41%
3 Month Change	21.42%
1 Year Change	43.22%
3 Year Change	74.09%
5 Year Change	185.06%
Change since IPO	292.57%

Recent updates

Shareholder Returns

	506690	IN Pharmaceuticals	IN Market
7D	-1.0%	-3.0%	-1.7%
1Y	43.2%	56.8%	45.0%

Return vs Industry: 506690 underperformed the Indian Pharmaceuticals industry which returned 57.5% over the past year.

Return vs Market: 506690 underperformed the Indian Market which returned 46.9% over the past year.

Price Volatility

Is 506690's price volatile compared to industry and market?
506690 volatility
506690 Average Weekly Movement	8.0%
Pharmaceuticals Industry Average Movement	5.9%
Market Average Movement	6.8%
10% most volatile stocks in IN Market	10.1%
10% least volatile stocks in IN Market	4.2%

Stable Share Price: 506690 has not had significant price volatility in the past 3 months.

Volatility Over Time: 506690's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1944	2,894	Pabitrakumar Bhattacharyya	www.unichemlabs.com

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. It offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management; and active pharmaceutical ingredients, as well as contract manufacturing services. The company also manufactures allopathic medicines, bulk drugs, and chemicals.

Unichem Laboratories Limited Fundamentals Summary

How do Unichem Laboratories's earnings and revenue compare to its market cap?
506690 fundamental statistics
Market cap	₹38.70b
Earnings (TTM)	₹145.69m
Revenue (TTM)	₹16.75b

265.6x

P/E Ratio

2.3x

P/S Ratio

Is 506690 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
506690 income statement (TTM)
Revenue	₹16.75b
Cost of Revenue	₹7.27b
Gross Profit	₹9.49b
Other Expenses	₹9.34b
Earnings	₹145.69m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	2.07
Gross Margin	56.63%
Net Profit Margin	0.87%
Debt/Equity Ratio	12.1%

How did 506690 perform over the long term?

See historical performance and comparison

506690 Stock Overview

Rewards

Risk Analysis

Unichem Laboratories Limited Competitors

BSE:524735

₹37.1b

BSE:530549

₹44.2b

BSE:524348

₹45.1b

BSE:509079

₹30.3b

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023)

Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024

Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg

Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023)

Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Recent updates

Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023)

Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024

Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg

Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023)

Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹3.32 loss in 1Q 2023)

Non-Executive Independent Director recently sold ₹10m worth of stock

Full year 2023 earnings released: ₹28.72 loss per share (vs ₹4.70 profit in FY 2022)

Third quarter 2023 earnings released: ₹9.08 loss per share (vs ₹2.01 loss in 3Q 2022)

Krka Reportedly Eyes Promoter Stake in Unichem Laboratories

Insufficient new directors

Second quarter 2023 earnings released: ₹10.04 loss per share (vs ₹1.82 loss in 2Q 2022)

Unichem Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Unichem Laboratories Limited Receives ANDA Approval for Extended Phenytoin Sodium Capsules USP, 100 Mg from United States Food and Drug Administration

Unichem Laboratories Limited Receives ANDA Approval for Carbamazepine Tablets USP

Unichem Laboratories Limited Receives ANDA Approval for Its Quetiapine Extended-Release Tablets

Unichem Laboratories Limited Receives ANDA Approval for its Labetalol Hydrochloride Tablets, USP 100 Mg, 200 Mg, and 300 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022

Upcoming dividend of ₹4.00 per share

Full year 2022 earnings released: EPS: ₹4.70 (vs ₹4.88 in FY 2021)

Unichem Laboratories Limited, Annual General Meeting, Aug 09, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories Limited Recommends Final Dividend for the Year Ended March 31, 2022

Unichem Laboratories Limited to Report Q4, 2022 Results on May 27, 2022

Insufficient new directors

Unichem Laboratories Limited Receives ANDA Approval for Its Divalproex Sodium Extended-Release Tablet

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings released: ₹1.82 loss per share (vs ₹1.24 profit in 2Q 2021)

Upcoming dividend of ₹4.00 per share

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Receives Tentative USFDA Approval for ANDA of Aripiprazole Tablets

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Recommends Dividend for the Year Ended March 31, 2021

Unichem Laboratories Limited Announces That It Has Received ANDA Approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg

Insider recently bought ₹2.3m worth of stock

Unichem Laboratories Limited Receives ANDA Approval for Its Guanfacine Tablets, USP 1 Mg and 2 Mg from the United States Food and Drug Administration

New 90-day high: ₹332

Unichem Laboratories Limited Receives Anda Approval for Its Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg from the United States Food and Drug Administration

New 90-day high: ₹294

Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.07 loss in 3Q 2020)

Unichem Laboratories Limited Receives ANDA Approval for its Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg from USFDA

Unichem Laboratories Limited to Report Q3, 2021 Results on Jan 30, 2021

New 90-day high: ₹286

Unichem Laboratories Limited Receives ANDA Approval from USFDA for Unichem's Celecoxib Capsules, 50 Mg, 100 Mg, 200 Mg, and 400 Mg

New 90-day high: ₹285

Unichem Laboratories Limited Receives ANDA Approval for Atenolol and Chlorthalidone Tablet

New 90-day low: ₹237

Second quarter 2021 earnings released: EPS ₹1.24

First half earnings released

Upcoming Dividend of ₹4.00 Per Share

First quarter earnings released

New 90-day high - ₹214

Shareholder Returns

Price Volatility

About the Company